secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001193125-24-129415
Event type: leadership
Sentiment:  negative
Materiality: 0.90
Item codes: 5.02, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Eiger BioPharma CFO resigns; appoints CRO amid Chapter 11 bankruptcy
--------------------------------------------------------------------

- CFO William G. Kachioff resigned effective April 29, 2024, as company restructures under Chapter 11.
- Board appointed Douglas Staut (Alvarez & Marsal) as Chief Restructuring Officer effective April 19, 2024.
- Company in Chapter 11 bankruptcy (Case 24-80040); relying on A&M for financial and accounting functions.
- Company warns trading in its securities is highly speculative and may result in total loss for holders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524129415/0001193125-24-129415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524129415/d833509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-129415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer